Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Observational Serial Chart Review of Repatha Use in European Subjects With Hyperlipidaemia

Next Previous
X
Search
Trial Profile

Observational Serial Chart Review of Repatha Use in European Subjects With Hyperlipidaemia

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 21 Feb 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Evolocumab (Primary)
  • Indications Hyperlipidaemia; Hyperlipoproteinaemia type IIa
  • Focus Therapeutic Use
  • Acronyms HEYMANS
  • Sponsors Amgen

    • Most Recent Events

    • 01 Feb 2023 The study was originally designed to have up to 12 months of follow up, However following a protocol amendment in February 2018, the follow up period was extended to 30 months.
    • 01 Feb 2023 Final Results(n=1951) assessing evolocumab persistence and discontinuation over 30 months of evolocumab treatment and to evaluate at a population level the variability in LDL-C level reductions during the study period published in the Atherosclerosis
    • 29 Aug 2022 Results of analyses assessing metrics of variability at population level in LDL-C reduction over time with evolocumab treatment presented at the ESC Congress 2022 - Annual Congress of the European Society of Cardiology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top